title: [Comparison of anti-angiogenic effect in vitro between ranibizumab and bevacizumab].
abstract: OBJECTIVE
  To evaluate the comparative in-vitro antiangiogenic effect of Bevacizumab and Ranibizumab.
  
  
  METHODS
  Endothelial venous umbilical cells culture (ECV304) cultivated in F12 media with addition of 10% Fetal Bovine Serum, were plaqued and treated with clinically relevant concentrations of Bevacizumab and Ranibizumab just after the scratch done in the middle of the culture (scratch methodology). Measurements of the linear size of the area free of cell proliferation were done 24, 48 and 72 hours after the scratch day point. All the experiments were done in triplicate and statistical analysis were done with T-student test.
  
  
  RESULTS
  Inhibitory effect was observed just at the concentrations of 0.5 and 0.7 mg/ml in both drugs. At 0.7 mg/ml, Ranibizumab demonstrated a more potent proliferative inhibitory effect than Bevacizumab. At the same concentration, Ranibizumab was three times more potent than Ranibizumab. Inhibitory effect was observed just in the first 24 hours for both drugs.
  
  
  CONCLUSIONS
  Ranibizumab demonstrates an increased effect when compared to Bevacizumab and this is related more to the different molar rate of each drug than related to a real better proliferative inhibitory effect.
authors.affiliation: Centro Interdisciplinar de Terapia Gênica, Universidade Federal de São Paulo, Brazil. retinaldc@terra.com.br
authors.forename: Alexandre Cupello
authors.initials: AC
authors.lastname: Souto
authors.forename: Juliana Terzi
authors.initials: JT
authors.lastname: Maricato
authors.forename: Priscila Martins Andrade
authors.initials: PM
authors.lastname: Denapoli
authors.forename: Juliana Maria Ferraz
authors.initials: JM
authors.lastname: Sallum
authors.forename: Sang Won
authors.initials: SW
authors.lastname: Han
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000068258:Bevacizumab; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects*; D006801:Humans; D000069579:Ranibizumab; D013997:Time Factors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab